Q1 Earnings Forecast for Immunocore Issued By HC Wainwright

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) – Equities research analysts at HC Wainwright upped their Q1 2026 EPS estimates for shares of Immunocore in a note issued to investors on Wednesday, March 4th. HC Wainwright analyst P. Trucchio now forecasts that the company will earn ($0.26) per share for the quarter, up from their previous estimate of ($0.28). HC Wainwright has a “Buy” rating and a $100.00 price objective on the stock. The consensus estimate for Immunocore’s current full-year earnings is ($0.94) per share. HC Wainwright also issued estimates for Immunocore’s Q3 2026 earnings at ($0.37) EPS, Q4 2026 earnings at ($0.41) EPS and FY2026 earnings at ($1.35) EPS.

Immunocore (NASDAQ:IMCR) last announced its quarterly earnings results on Wednesday, February 25th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.32). Immunocore had a negative net margin of 8.88% and a negative return on equity of 9.20%. The company had revenue of $104.48 million for the quarter, compared to analysts’ expectations of $145.48 million. During the same quarter in the prior year, the firm earned ($0.47) EPS. Immunocore’s quarterly revenue was up 24.3% compared to the same quarter last year.

A number of other research firms have also recently commented on IMCR. Weiss Ratings restated a “sell (e+)” rating on shares of Immunocore in a research note on Thursday, January 22nd. Morgan Stanley increased their price target on shares of Immunocore from $34.00 to $36.00 and gave the stock an “equal weight” rating in a research note on Monday, November 10th. UBS Group set a $55.00 price objective on shares of Immunocore and gave the stock a “buy” rating in a research note on Wednesday, January 7th. Zacks Research lowered shares of Immunocore from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 25th. Finally, Wall Street Zen cut Immunocore from a “buy” rating to a “hold” rating in a research report on Saturday, January 31st. Eight equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Immunocore currently has a consensus rating of “Moderate Buy” and an average target price of $61.30.

Immunocore Stock Performance

Immunocore stock opened at $32.94 on Friday. Immunocore has a fifty-two week low of $23.15 and a fifty-two week high of $40.71. The stock’s 50 day simple moving average is $33.11 and its two-hundred day simple moving average is $34.32. The company has a debt-to-equity ratio of 1.03, a quick ratio of 4.01 and a current ratio of 4.04. The stock has a market cap of $1.66 billion, a price-to-earnings ratio of -47.06 and a beta of 0.78.

Insider Activity at Immunocore

In related news, insider David M. Berman sold 5,965 shares of the stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $32.35, for a total transaction of $192,967.75. Following the sale, the insider directly owned 5,859 shares of the company’s stock, valued at approximately $189,538.65. This represents a 50.45% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Bahija Jallal sold 11,474 shares of Immunocore stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $32.35, for a total transaction of $371,183.90. Following the completion of the transaction, the chief executive officer directly owned 12,343 shares of the company’s stock, valued at $399,296.05. This trade represents a 48.18% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 19,137 shares of company stock valued at $619,082. 10.40% of the stock is owned by insiders.

Institutional Trading of Immunocore

Several institutional investors have recently added to or reduced their stakes in IMCR. XTX Topco Ltd purchased a new position in shares of Immunocore in the fourth quarter worth $763,000. Voloridge Investment Management LLC purchased a new stake in shares of Immunocore during the fourth quarter valued at $978,000. Vestal Point Capital LP bought a new stake in Immunocore in the 4th quarter worth about $20,305,000. Virtus Investment Advisers LLC increased its holdings in Immunocore by 48.9% in the 4th quarter. Virtus Investment Advisers LLC now owns 18,569 shares of the company’s stock worth $645,000 after buying an additional 6,097 shares in the last quarter. Finally, Susquehanna Portfolio Strategies LLC raised its position in Immunocore by 162.0% in the 4th quarter. Susquehanna Portfolio Strategies LLC now owns 27,607 shares of the company’s stock worth $958,000 after buying an additional 17,069 shares during the last quarter. 84.50% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Immunocore

Here are the key news stories impacting Immunocore this week:

• Positive Sentiment: HC Wainwright maintained a “Buy” rating and a $100 price target on IMCR, which supports positive investor sentiment despite model tweaks. Read More.
• Positive Sentiment: HC Wainwright slightly raised its Q1 2026 EPS estimate to a ($0.26) loss from ($0.28), a small improvement for near-term earnings expectations. Read More.
• Neutral Sentiment: HC Wainwright trimmed several long-range targets modestly (FY2027–FY2030 EPS down by cents in most cases — e.g., FY2028 $4.07 from $4.10; FY2029 $7.50 from $7.55; FY2030 $11.20 from $11.26). These small adjustments reflect model fine-tuning rather than a material strategy change. Read More.
• Negative Sentiment: HC Wainwright lowered near-term EPS for Q3 and Q4 2026 (Q3 to ($0.37) from ($0.35); Q4 to ($0.41) from ($0.39)) and nudged FY2026 to ($1.35) from ($1.34). Those downward revisions — combined with HCW’s FY2026 view that is meaningfully below consensus (~($0.94)) — are potential near-term negatives for sentiment and could cap upside until clinical or commercial progress narrows the gap. Read More.

Immunocore Company Profile

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.